ZNTL · Insider Trading
Zentalis Pharmaceuticals, Inc. Common Stock
Every open-market purchase and sale reported by ZNTL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-01 | Ingmar Bruns | Chief Medical Officer | A | +9,727 | +$21.20K |
| 2026-08-19 | WALTERS GROUP | 10%+ Owner | Buy | +13,005,000 | +$45.52M |
| 2026-06-18 | Enoch Kariuki | Director | A | +57,100 | — |
| 2026-06-18 | Luke Nathaniel Walker | Director | A | +57,100 | — |
| 2026-06-18 | Jan Skvarka | Director | A | +57,100 | — |
| 2026-06-18 | Scott Dunseth Myers | Director | A | +57,100 | — |
| 2026-06-18 | David Michael Johnson | Director | A | +57,100 | — |
| 2026-05-27 | Shannon Campbell | Director | A | +114,200 | — |
| 2026-02-10 | Julia Marie Eastland | CEO & President | Sell | −8,755 | −$21.24K |
| 2026-02-10 | Vincent Vultaggio | PAO and PFO | Sell | −40,224 | −$97.56K |
| 2026-02-10 | Ingmar Bruns | Chief Medical Officer | Sell | −3,297 | −$8.00K |
| 2026-02-04 | Vincent Vultaggio | PAO and PFO | Sell | −3,096 | −$7.88K |
| 2026-01-09 | James B Bucher | Chief Legal Officer | A | +100,000 deriv. | — |
| 2026-01-09 | Julia Marie Eastland | CEO & President | A | +775,000 deriv. | — |
| 2026-01-09 | Vincent Vultaggio | PAO and PFO | A | +100,000 deriv. | — |
| 2026-01-09 | Ingmar Bruns | Chief Medical Officer | A | +365,000 deriv. | — |
| 2026-01-08 | William Thurman Walters | 10%+ Owner | Buy | +19,379,919 | +$23.26M |
| 2025-12-15 | David E. Goel | 10%+ Owner | Sell | −15,000,000 | −$19.95M |
| 2025-10-01 | James B Bucher | Chief Legal Officer | A | +400,000 deriv. | — |
| 2025-06-18 | Scott Dunseth Myers | Director | A | +57,603 | — |
| 2025-06-18 | Jan Skvarka | Director | A | +57,603 | — |
| 2025-06-18 | Luke Nathaniel Walker | Director | A | +57,603 | — |
| 2025-06-18 | David Michael Johnson | Director | A | +57,603 | — |
| 2025-06-18 | Enoch Kariuki | Director | A | +57,603 | — |
| 2025-04-30 | Scott Dunseth Myers | Director | Buy | +21,000 | +$29.37K |
| 2025-02-12 | Ingmar Bruns | Chief Medical Officer | Buy | +20,000 | +$45.66K |
| 2025-02-05 | Ingmar Bruns | Chief Medical Officer | A | +16,629 | — |
| 2025-02-05 | Andrea Paul | Chief Legal Officer | MIXED | +920,811 | −$22.64K |
| 2025-02-05 | Julia Marie Eastland | CEO & President | A | +59,388 | — |
| 2025-02-05 | Mark Lackner | Chief Scientific Officer | MIXED | +321,539 | −$24.59K |
| 2025-02-05 | Vincent Vultaggio | PAO and Interim PFO | MIXED | +155,971 | −$4.48K |
| 2025-02-04 | Luke Nathaniel Walker | Director | Buy | +14,200 | +$24.97K |
| 2025-02-04 | Jan Skvarka | Director | Buy | +60,000 | +$103.45K |
| 2025-02-04 | Julia Marie Eastland | CEO & President | Buy | +28,500 | +$49.34K |
| 2025-01-03 | Mark Lackner | Chief Scientific Officer | Sell | −4,411 | −$13.76K |
| 2024-12-03 | Julia Marie Eastland | CEO & President | A | +3,028,800 deriv. | — |
| 2024-12-03 | Ingmar Bruns | Chief Medical Officer | A | +712,650 deriv. | — |
| 2024-11-13 | Scott Dunseth Myers | Director | A | +260,192 | — |
| 2024-10-04 | Vincent Vultaggio | Principal Accounting Officer | Sell | −1,603 | −$5.10K |
| 2024-06-21 | Enoch Kariuki | Director | A | +41,581 | — |
| 2024-06-21 | David Michael Johnson | Director | A | +48,429 | — |
| 2024-06-21 | Jan Skvarka | Director | A | +41,581 | — |
| 2024-05-31 | Cam Gallagher | President, Interim CFO | Sell | −9,597 | −$114.97K |
| 2024-05-29 | Luke Nathaniel Walker | Director | A | +72,481 | — |
| 2024-05-09 | Diana Hausman | Chief Medical Officer | Sell | −3,356 | −$42.35K |
| 2024-02-12 | Epperly Melissa B, | Chief Financial Officer | Sell | −2,573 | −$29.44K |
| 2024-02-12 | Cam Gallagher | President | Sell | −1,173 | −$13.42K |
| 2024-02-05 | Diana Hausman | Chief Medical Officer | A | +337,500 | — |
| 2024-02-05 | Epperly Melissa B, | Chief Financial Officer | MIXED | +66,331 | −$100.04K |
| 2024-02-05 | Cam Gallagher | President | MIXED | +180,948 | −$133.31K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| WALTERS GROUP | 10%+ Owner | 17,844,973 | $36.94M |
| William Thurman Walters | 10%+ Owner | 13,509,973 | $27.97M |
| David E. Goel | 10%+ Owner | 6,459,973 | $13.37M |
| Andrea Paul | Chief Legal Officer | 1,070,784 | $2.22M |
| Mark Lackner | Chief Scientific Officer | 527,224 | $1.09M |
| Scott Dunseth Myers | Director | 395,895 | $819.50K |
| David Michael Johnson | Director | 307,521 | $636.57K |
| Jan Skvarka | Director | 264,254 | $547.01K |
| Luke Nathaniel Walker | Director | 201,384 | $416.86K |
| Enoch Kariuki | Director | 194,465 | $402.54K |
| Vincent Vultaggio | PAO and PFO | 156,779 | $324.53K |
| Shannon Campbell | Director | 114,200 | $236.39K |
| Julia Marie Eastland | CEO & President | 80,022 | $165.65K |
| Ingmar Bruns | Chief Medical Officer | 43,059 | $89.13K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ZNTL quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.